InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by David Matthew T, Chief Executive Officer. Director active across 1 company, notably CorMedix Inc.. In total, 6 disclosures have been published. Split: 6 buys · 0 sell. Total volume traded: €25k. History available since 17 November 2021. The latest transaction was filed on 6 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
1,000 shares@ US$4.500.0004% mcap16.0% of flowCommon StockSEC:0001213900-21-064006:0
Ideal exit: 2 Sept 2022 (T+270)
1,000 shares@ US$4.5032.0% of flowCommon StockSEC:0001213900-21-064007
Ideal exit: 2 Sept 2022 (T+270)
1,000 shares@ US$4.5032.0% of flowCommon StockSEC:0001213900-21-064006
Ideal exit: 2 Sept 2022 (T+270)
1,000 shares@ US$4.500.0004% mcap16.0% of flowCommon StockSEC:0001213900-21-064007:0
Ideal exit: 2 Sept 2022 (T+270)
1,000 shares@ US$5.070.0005% mcap18.0% of flowCommon StockSEC:0001213900-21-060724:0
Ideal exit: 14 Aug 2022 (T+270)
1,000 shares@ US$5.0736.0% of flowCommon StockSEC:0001213900-21-060724
Ideal exit: 14 Aug 2022 (T+270)
6 of 6 declarations
About David Matthew T
Matthew T. David serves as Interim CEO and Chief Financial Officer at CorMedix Inc. He oversees the company's financial and strategic operations, ensuring compliance with regulatory standards. Matthew plays a key role in resource management and supporting growth initiatives.
